DxS Wins North West Biomedical Company of the Year Award

Personalised medicine company, DxS has won the 2008 Biomedical Company of the Year Award from Bionow, the Northwest Regional Development Agency’s (NWDA) biomedical cluster support group. The prestigious award was sponsored by AstraZeneca/MedImmune.

Dr John Stageman, VP R&D Science Affairs at AstraZeneca, presenting the award, said: “I’m delighted to present this important award to DxS. 2008 has been an exceptional year for the company, not only in securing a number of significant deals with major pharmaceutical companies but also in creating a strong portfolio of novel tests to improve the effectiveness of cancer treatment. We are proud to recognise the achievements of DxS as a pioneering company and we are confident it is now in a position to make a very significant impact on this increasingly important field of medicine.”

Dr Stephen Little, CEO of DxS said: “I am very pleased to accept this award on behalf of DxS. It is excellent news for the company and shows

just how far we have come this year. We are in the vanguard of personalised medicine with our cancer companion diagnostics and we

anticipate 2009 to be a very exciting year with further products in development.”